CORT News and Press, Corcept Therapeutics Incorporated From 12/08/22

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ho...

Corcept Therapeutics Incorporated (CORT) Q3 2022 Earnings Conference Call November 03, 2022 05:00 PM ET Company Participants Joseph Belanoff - CEO and President Atabak Mokari - CFO Bill Guyer - CDO Charlie Robb - CBO Sean Maduck - President, Corcept Endoc...

Corcept Therapeutics press release ( NASDAQ: CORT ): Q3 GAAP EPS of $0.30. Revenue of $101.7M (+5.8% Y/Y). Shares -2.81% . For further details see: Corcept Therapeutics GAAP EPS of $0.30, revenue of $101.7M

MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of ...

The market may be down 23% this year, but that hasn't stopped a trio of drug companies from powering onward. Vertex Pharmaceuticals , (NASDAQ: VRTX) Catalyst Pharmaceuticals , (NASDAQ: CPRX) and Corcept Therapeutics (NASDAQ: CORT) are all rising sharply in contrast t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The markets have delivered one of the worst years in the past several decades. As a result, investors are left searching for under-the-radar stocks that have been passed over due to all the bad news. What constitutes a...

When it comes to growth stocks in the U.S. stock market, few companies have the reputation of delivering stellar returns than Amazon.com ( NASDAQ:AMZN ). However, big tech companies are not always winners for growth-seeking investors. As of this writing, Amazon stock tra...

Corcept Therapeutics ( NASDAQ: CORT ) on Tuesday said it had started a phase 2 trial of its modulator dazucorilant for the treatment of neurodegenerative disease amyotrophic lateral sclerosis (ALS). The mid-stage study, called DAZALS, is expected to enroll 198 ALS patients...

MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of ...

Corcept Therapeutics Incorporated ( NASDAQ: CORT ), the maker of Cushing’s syndrome medication Korlym, has extended its partnership with specialty pharmacy Optime Care, Inc., for U.S. distribution of the treatment. As part of the Sep. 16 amendment to the pharmaceuti...